Meeting
2018 ASCO Annual Meeting
Pharmacodynamic characterization of eryaspase (L-asparaginase encapsulated in red blood cells) in combination with chemotherapy in a phase 2/3 trial in patients with relapsed acute lymphoblastic leukemia (NCT01518517).
Authors
Iman El-Hariry
Erytech Pharma, Cambridge, MA
Iman El-Hariry , Karine Aguera , Frank Hoke , Kenneth Swart , Adam Hamm , Richard Kay , Philip Lorenzi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Acute Leukemia
Clinical Trial Registration Number
NCT01518517
Citation
J Clin Oncol 36, 2018 (suppl; abstr 7049)
DOI
10.1200/JCO.2018.36.15_suppl.7049
Abstract #
7049
Poster Bd #
109
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
A phase II/III study of JZP-458 in patients with acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LBL) who are hypersensitive to E. coli-derived asparaginases.
First Author: Luke Maese
Poster
2020 ASCO Virtual Scientific Program
Tisagenlecleucel (Tisa) for relapsed/refractory (r/r) acute lymphoblastic leukemia (ALL): B2001X study focusing on prior exposure to blinatumomab (BLINA) and inotuzumab (INO).
First Author: Joerg Krueger
Poster
2020 ASCO Virtual Scientific Program
A phase II study of MT-3724, a novel CD20-targeting engineered toxin body, to evaluate safety, pharmacodynamics, and efficacy in subjects with relapsed or refractory diffuse large B-cell lymphoma.
First Author: Adolfo Enrique Diaz Duque
Poster
2019 ASCO Annual Meeting
Phase II results of mitoxantrone in combination with clofarabine in children with relapsed/refractory acute leukemia.
First Author: Jessica Hochberg